TrialThe oncologist2023

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.

Cristiane Bergerot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.